20 Dec 2013 07:00
Omega Diagnostics Group PLC
("Omega" or the "Company")
CD4 Update
Omega (AIM: ODX), the medical diagnostics company focused on allergy, food intolerance and infectious disease, announces the following update on its CD4 technology transfer project.
As reported last month with the interim results, we selected a preferred manufacturing protocol to proceed to a three-batch validation. The Company is pleased to announce that it has produced a first reference batch which, when tested on patient samples, has produced results which are within the agreed design specification for the accuracy of the test and which demonstrate a significant reduction in the levels of variability previously reported.
This is an important milestone in the technology transfer project and we will proceed to test the protocol with further independent manufacturing runs.
The Board has increased confidence in successfully completing the three-batch validation and, given the proximity to Christmas, we will provide a further update early in the New Year.
Contacts:
Omega Diagnostics Group PLC | Tel: 01259 763 030 |
Andrew Shepherd, Chief Executive | www.omegadiagnostics.com |
Kieron Harbinson, Group Finance Director | |
Jag Grewal, Group Sales and Marketing Director | |
finnCap Ltd | Tel: 020 7220 0500 |
Geoff Nash/Christopher Raggett (Corporate Finance) | |
Stephen Norcross/Mia Gardner (Corporate Broking) | |
Walbrook PR Limited | Tel: 020 7933 8780 or omega@walbrookpr.com |
Paul Cornelius | Mob: 07866 384 707 |
Lianne Cawthorne | Mob: 07584 391 303 |